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Clinical, Pathological and Immunohistochemical Evaluation  
of a Primary Hemangiosarcoma in a Pinscher Dog
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ABSTRACT
Background: Hemangiosarcoma (HSA) is a malignant tumor that arises from the vascular endothelium affecting more 
often dogs than other species as cats, cows and horses. It comprises approximately 2% of all tumors in dogs. The most 
common primary site for the HSA in dogs is the spleen, and other locations include the right atrium, pericardium, liver and 
prostate. Other authors have reported this tumor in lungs, kidney, oral cavity, muscle, bone, urinary bladder, left ventricle, 
tongue and retroperitoneum. Due to the importance of the HSA in canine species, the aim of this study was to describe the 
clinical and pathological findings, besides therapeutic protocol in an unusual case of HSA.
Case: A six-year-old male pinscher was referred to the veterinary hospital with a history of cyanosis and choking. The animal 
was submitted to radiographic examination in lateral cervical view, which identified the presence of a mass of 1.2 cm in 
diameter near the pharynx. In order to evaluate the oral cavity, general anesthesia was performed, and it was possible to see 
a soft, rosy, circumscribed and vascularized lump in pharyngeal region. Due to suspicion of neoplasm, excisional biopsy 
without surgical margin was performed. The histopathological exam diagnosed hemangiosarcoma. Immunohistochemistry 
against vimentin, factor VIII, VEGF and Ki67 was performed and confirmed diagnosis of low grade hemangiosarcoma. 
Antineoplastic chemotherapy protocol was initiated with doxorubicin and cyclophosphamide every 21 days totaling six 
sessions. However, the animal died after the cyclophosphamide intoxication with a three-fold recommended dose (660 
mg/m² total in the last session), showing a median survival rate of 220 days. 
Discussion: The most common primary site for HSA in dogs is the spleen. The pharyngeal location is rare, with only a 
few reports in literature. In the present case, solitary tumor was observed in pharynx with no involvement of other organs, 
evidenced by radiographic examination, abdominal ultrasound and echocardiogram, suggesting that pharynx was the 
primary location of the tumor. Main features of HSA comprise a solitary nodule or multifocal lesions within the organ or 
widely disseminated. Histologically, they consist of pleomorphic immature endothelial cells with formation of vascular 
spaces with variable amount of blood and/or thrombi. In some cases, HSA shows a polymorphic subtype and immuno-
histochemistry is necessary to provide a definitive diagnosis. The sample was submitted to histopathological examination 
which revealed proliferation of endothelial cells with pronounced pleomorphism ranging from polygonals to ovoid, sparse 
cytoplasm, round to oval nucleus with visible nucleolus, few mitotic figures, some of them, aberrant, which confirmed 
diagnosis of HAS. Due to the unusual location, we performed immunohistochemical staining for vimentin, factor VIII, 
VEGF and Ki67 antibodies to confirm mesenchymal origin of the tumor. In IHC, it was possible to identify positive reac-
tion for vimentin protein, factor VIII, VEGF and few Ki67 positive cells, confirming histopathological diagnosis. Despite 
literature describes an aggressive biological behavior of canine HSA, with common occurrence of metastasis, recurrence 
was not observed at the site of the removal of the tumor. In histopathological evaluation, it was observed low number of 
mitoses, besides the low Ki67 expression on IHC, featuring a low grade tumor with minor ability to metastasize. To the 
author’s knowledge, this case describes an unusual presentation of HSA, with low metastatic potential, in which chemo-
therapy protocol achieved survival time of 220 days.
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INTRODUCTION
Hemangiosarcoma (HSA) is a malignant tumor 
that arises from the vascular endothelium affecting 
more often dogs than other species as cats, cows and 
horses [19,23]. It comprises approximately 2% of all 
tumors in dogs [8] and 45% to 51% of splenic tumors 
[3,21].  Affects most frequently middle-aged to older 
animals, although there are reports of dogs with less 
than 3 years of age affected by the disease [5].
The most common primary site for the HSA 
in dogs is the spleen, and other locations include the 
right atrium, pericardium, liver and prostate [5]. Other 
authors report this tumor in lungs, kidney, oral cavity, 
muscle, bone, urinary bladder, left ventricle, tongue 
and retroperitoneum [1,4,10-12].
Main features of HSA comprise a solitary nod-
ule, or multifocal lesions within the organ or widely 
disseminated. The nodules show varying sizes, are light 
gray to red or dark purple; soft or flabby, often filled by 
blood or necrotic areas on the surface. They are little 
circumscribed and not encapsulated, often adhered to 
adjacent organs and friable [24]. 
Histologically, they consist of pleomorphic 
immature endothelial cells with formation of vascular 
spaces with variable amount of blood and/or thrombi 
[7]. In some cases, HSA shows a polymorphic subtype 
and immunohistochemistry is necessary to provide a 
definitive diagnosis. Von Willebrand’s factor (factor 
VIII related antigen), CD31 or platelet endothelial 
cell adhesion molecule (PECAM-1) can be used to 
demonstrate endothelial origin and confirm HSA di-
agnosis [7,15,25]. 
Due to the importance of the HSA in canine 
species, the aim of this study was to describe the 
clinical and pathological findings, besides therapeutic 
protocol in an unusual case of HSA.
CASE
A six-year-old male Pinscher was referred to 
the Veterinary Hospital at Federal University of Mato 
Grosso do Sul (UFMS), with a history of choking 
and cyanosis. On physical examination, it was noted 
difficult breathing and dry cough with no changes in 
physiological parameters. Due to respiratory distress, 
the animal was forwarded to radiographic examination 
in lateral cervical view, which identified the presence of 
a mass of 1.2 cm in diameter near the pharynx (Figure 
1). In order to evaluate the oral cavity of the animal, 
inducing anesthesia was performed with 1% propofol 
solution (Diprivan®)1 and for maintenance isoflurine 
was used (Isoflurane®)2.The procedure allowed the 
visualization of a soft, pink, circumscribed and vas-
cularized lump in pharyngeal region (Figure 2). Due 
to suspicion that the mass as a neoplasm, excisional 
biopsy was performed, without possibility of surgical 
margin due to the location.
Figure 1. Lateral cervical view of a Pinscher observing the presence of a 
mass of 1.2 cm in diameter near the pharynx.
Figure 2. Canine. 6-year-old. Oral exam showing a soft, rosy, circumscribed 
and vascularized lump in pharyngeal region.
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The sample was submitted to histopathologi-
cal examination which revealed proliferation of endo-
thelial cells with pronounced pleomorphism ranging 
from polygonals to ovoid, sparse cytoplasm, round 
to oval nucleus with visible nucleolus, few mitotic 
figures, some of them, aberrant, which confirmed 
diagnosis of HSA. After surgical excision, remission 
of respiratory signs was observed. Due to the unusual 
location, we performed immunohistochemical stain-
ing for vimentin, factor VIII, VEGF and Ki67 anti-
bodies to confirm mesenchymal origin of the tumor. 
The immunohistochemical staining was performed 
using peroxidase method and 3,3’ diaminobenzidine 
tetrachloride (DAB). The slides were dewaxed in 
xylol and rehydrated in graded ethanol. For antigen 
retrieval the slides were incubated in citrate buffer (pH 
6.0) in a pressure cooker (Pascal®; Dako, Carpinteria, 
CA, USA). 
Anti-factor VIII was detected with a monoclo-
nal antibody (Abcam, ab20837) at a 1 in 500 dilution, 
applied for 45 min. The antibody against Vimentin 
was a monoclonal mouse antibody (V9, Invitrogen), 
used at a 1:300 dilution for 45 min. Ki67 antibody was 
monoclonal mouse antibody (Dako Cytomation) which 
was used at a 1 in 50 dilution for 45 min and a VEGF 
monoclonal antibody (Dako Cytomation) at a 1 in 50 
dilution for 45 min. 
After this, slides were placed on Dako Cyto-
mation autostainer platform. The immunolabelling 
was performed by the Histofine method (414154F, 
Nichirei Biosciences, Tokyo, JP). The sections were 
then counterstained with haematoxylin, dehydrated, 
mounted in Etellan, and examined with a light mi-
croscope at 400X magnification. In all immunola-
belled batches, omission of the primary antibody and 
replacement with the diluting solution alone served 
as a negative control. Positive control consisted of 
normal canine ovary gland for estrogen and pro-
gesterone receptor, carcinoma known positive for 
cytokeratin, mesenchymal tumor known positive 
for vimentin. A negative control was performed for 
all antibodies by omitting the primary antibody and 
substituting with Tris-buffered saline. In IHC it was 
possible to identify positive reaction for vimentin 
protein, factor VIII, VEGF and few Ki67 positive 
cells, confirming histopathological diagnosis (Fig-
ures 3 & 4).
Due to the unfavorable prognosis of HSA it 
was recommended neoadjuvant chemotherapy, but 
the owner did not agree consent. Three months after 
surgery, clinical evaluation and x-rays of the dog were 
performed and no changes that could indicate tumor 
recurrence have been found. At that moment, the 
owner decided to accept neoadjuvant chemotherapy. 
Protocol was established with doxorubicin hydrochlo-
ride (Doxorubicin hydrochloride 10 mg)3 at a dose 
of 1 mg/kg every three weeks and cyclophosphamide 
(remanipulated at DrogaVet veterinary pharmacy; 
Genuxal® 50 mg)4 at a dose of 50 mg/m² orally on 
days D2, D3, D4, D5 (full dose 200 mg/m²), starting 
two days after doxorubicin, totaling six sessions. 
During treatment, blood examinations have showed 
some alterations such as leukopenia, thrombocyto-
penia and increased serum concentration of alanine 
aminotransferase (ALT).
However, during the last session of che-
motherapy the owner mistakenly administered 
220 mg/m² of cyclophosphamide per day for three 
days (total of 660 mg/m²). After this episode, the 
animal presented vomiting, anorexia, pollakiuria, 
stranguria and hematuria. The dog was forwarded to 
abdominal ultrasound, which revealed hyperechoic 
liver and kidneys and an irregular and thick blad-
der wall. Urine was submitted for urinalysis, which 
demonstrated proteinuria, hematuria and epithelial 
cells, suggesting sterile hemorrhagic cystitis by 
cyclophosphamide. The red blood count showed 
intense leukopenia and thrombocytopenia (100 leu-
kocytes [reference interval 6,000 - 17,000 x 10 m³] 
and seven thousand platelets [reference interval 
200,000 - 500,000], respectively).
The animal was put on intensive care with 
fluidtherapy NaCl 0.9% (cloreto de sódio® 0,9%)4, 
Propionyobacterium acnes as an immunomodulator 
at a dose of 1mL IM (Infervac®)5, 8 mg/kg of a single 
dose intravenous of sodium cefovecina (Convenia®)6, 
maropitant 1 mg/kg, once a day, (Cerenia®)6, meloxi-
cam 0.15 mg/kg once a day (Maxicam® 0.5 mg)7 and 
Silymarin 10 mg/kg every 12 h (Legalon®)8. However, 
two days after hospitalization, the animal presented 
intense crisis of dyspnea and died. The owner did not 
authorize the necropsy.
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Figure 3. Photomicrographs of canine hemangiosarcoma, immunohis-
tochemistry, anti-factor VIII antibody. It is possible to note the diffuse 
positive immunoreaction by mesenchymal cells, as well as the endothelial 
cells (internal positive control). DAB, 20x [50 μm].
Figure 4. Photomicrographs of canine hemangiosarcoma, immunohisto-
chemistry, anti-VEGF antibody. Positive cytoplasmic immunoreaction by 
neoplastic cells. DAB, 20x [50 μm].
DISCUSSION
The most common primary site for HSA in 
dogs is the spleen [5]. The pharyngeal location is rare, 
with only a few reports in literature [6,9,17]. In the 
present case, solitary tumor was observed in pharynx 
with no involvement of other organs, evidenced by 
radiographic examination, abdominal ultrasound and 
echocardiogram, suggesting that pharynx was the pri-
mary location of the tumor, which is not in accordance 
with previous reports that describe the location of 
pharynx as metastatic focus of the neoplasm.
Despite literature describes an aggressive 
biological behavior of canine HSA, with common 
occurrence of metastasis [26], recurrence was not 
observed at the site of the removal of the tumor, nor 
the presence of metastatic structures in other organs 
during the period of treatment. This fact can be associ-
ated to a unique biological behavior of this tumor in 
this location. In histopathological evaluation, it was 
observed low number of mitoses, besides the low Ki67 
expression on IHC, featuring a low grade tumor with 
minor ability to metastasize. 
Chemotherapy protocols using doxorubicin or 
vincristine, and cyclophosphamide have been reported 
to lead to the best survival time for canine HAS [2]. In 
this case, it was observed good acceptance to antineo-
plastic treatment, with minimal side effects. However, 
the dog died after 220 days of starting treatment because 
of cyclophosphamide intoxication. The combination of 
surgery and chemotherapy can increase the survival time 
(median of 140-180 days), so that 33% of the treated 
animals can overcome a year of survival [14]. Another 
article reported an average survival time for splenic HSA 
of 202 days treated with doxorubicin and cyclophos-
phamide [20]. One study used the histological degree 
scheme and it has been shown that dogs with low-grade 
neoplasms have better prognosis compared to high-
intermediate-grade neoplasms [16]. This corroborates 
the findings found in IHC of this animal, in which it 
was observed low Ki67 expression and low number of 
mitoses, suggesting less ability to metastasize.
In this case, the animal was expected to have a 
survival rate higher than 220 days, but it was decreased 
due to the intoxication of cyclophosphamide. Cyclo-
phosphamide is a nitrogen mustard that may be given 
orally in dogs, showing low toxicity, which include 
bone marrow suppression and sterile haemorrhagic 
cystitis [18,22]. One study observed the development 
of hemorrhagic cystitis in three dogs in the indicated 
therapeutic dose (100-250 mg/m²) [18]. Although 
hemorrhagic cystitis is unusual in conventional doses, 
high doses can lead to this complication as the case de-
scribed, which took 150 mg total of cyclophosphamide 
(660 mg/m2), corresponding to three times the total 
recommended dose. The dog showed severe signs of 
intoxication, with myelosuppression and hemorrhagic 
cystitis, and died even after conservative treatment. In 
human patients, it was observed pathological evidence 
of hemorrhagic cystitis after a single dose of 660 mg/
m² of cyclophosphamide [13].
To the author’s knowledge, the case describes 
an unusual presentation of HSA, with low metastatic 
potential, in which chemotherapy protocol achieved 
survival time of 220 days.
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